ACHV Share Price Performance
US$2.65
-0.02 (-0.75%)
82.8% undervalued intrinsic discount
US$15.38
Fair Value
Price US$2.65
AnalystConsensusTarget US$15.38
AnalystHighTarget US$25.00
Fair ValueUS$15.38
Share Pricen/a
Achieve Life Sciences, Inc. Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 29 Fair Values set on narratives written by author
ACHV Community Narratives
AN
Fair Value US$15.38 82.8% undervalued intrinsic discount
Regulatory Tailwinds And Public Health Demand Will Support This Nicotine Cessation Opportunity
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value US$25 89.4% undervalued intrinsic discount
FDA Priority Voucher And Smoking Cessation Tailwinds Will Transform This Undervalued Biotech Story
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Regulatory Tailwinds And Public Health Demand Will Support This Nicotine Cessation Opportunity
Catalysts About Achieve Life Sciences Achieve Life Sciences is a clinical stage biopharmaceutical company focused on developing cytisinicline as a treatment for nicotine dependence in smokers and vapers. What are the underlying business or industry changes driving this perspective?Read more
17
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$15.38
82.8% undervalued intrinsic discount
Fair Value
Profit Margin
22.4%
Future PE
37x
Price in 2029
US$0
FDA Priority Voucher And Smoking Cessation Tailwinds Will Transform This Undervalued Biotech Story
Catalysts About Achieve Life Sciences Achieve Life Sciences is a biopharmaceutical company focused on developing and commercializing cytisinicline as a treatment for nicotine dependence in smokers and people who vape. What are the underlying business or industry changes driving this perspective?Read more
15
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$25
89.4% undervalued intrinsic discount
Fair Value
Profit Margin
42.91%
Future PE
15.06x
Price in 2029
US$0
Trending Discussion
Recently Updated Narratives
AN
Regulatory Tailwinds And Public Health Demand Will Support This Nicotine Cessation Opportunity
Fair Value: US$15.38 82.8% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
FDA Priority Voucher And Smoking Cessation Tailwinds Will Transform This Undervalued Biotech Story
Fair Value: US$25 89.4% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Achieve Life Sciences, Inc. Key Details
About ACHV
- Founded
- n/a
- Employees
- 25
- CEO
- WebsiteView website
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.
